Author

T. Haferlach

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Organism:human· 4 Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Approach:statistical model· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2

Frequent Co-Authors

F. Grebien· 2 shared T. Eder· 2 shared A. Bagchi· 1 shared A. Boersma· 1 shared A. Deshpande· 1 shared A. G. X. Zeng· 1 shared A. Krippner-Heidenreich· 1 shared A. Mitchell· 1 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. Grebien

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Single-cell transcriptional mapping reveals genetic and non-genetic determinants of aberrant differentiation in AML

A. G. X. Zeng, I. Iacobucci, S. Shah, A. Mitchell, G. Wong, S. Bansal, D. Chen, Q. Gao, H. Kim, J. A. Kennedy, M. D. Minden, T. Haferlach, C. G. Mullighan, J. E. Dick

The paper constructs a reference atlas of human hematopoiesis and maps AML differentiation patterns, revealing genetic and non-genetic factors driving aberrant differentiation in leukemia.

bioRxiv · Dec 26, 2023Cancer Biology

The neuronal homeobox transcription factor HMX3 is a crucial vulnerability factor in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia

S. Arza-Apalategi, B. M. H. Heuts, S. M. Bergevoet, R. Meering, D. Gilissen, P. W. T. C. Jansen, A. Krippner-Heidenreich, P. J. M. Valk, M. Vermeulen, O. Heidenreich, T. Haferlach, J. H. Jansen, J. H. A. Martens, B. A. van der Reijden

The paper identifies HMX3 as a critical vulnerability in MECOM-negative KMT2A::MLLT3 AML, showing it promotes proliferation and blocks differentiation.

bioRxiv · Nov 7, 2023 · PreprintCancer Biology

TET2 lesions enhance the aggressiveness of CEBPA-mutant AML by rebalancing GATA2 expression

E. Heyes, A. S. Wilhelmson, A. Wenzel, G. Manhart, T. Eder, M. B. Schuster, E. Rzepa, S. Pundhir, T. D'Altri, C. Gentil, M. Meggendorfer, J. Schwaller, T. Haferlach, F. Grebien, B. T. Porse

This study identifies GATA2 as a target of the CEBPA-TET2 mutational axis in AML, showing how TET2 lesions rebalance GATA2 expression and enhance disease aggressiveness.

bioRxiv · Mar 28, 2023Cancer Biology

STAT5 Gain-of-Function Variants Promote Precursor T-Cell Receptor Activation to Drive T-Cell Acute Lymphoblastic Leukemia

T. Suske, H. Sorger, F. Ruge, N. Prutsch, M. W. Zimmerman, T. Eder, B. Maurer, C. Wagner, S. Schoenefeldt, K. Spirk, A. Pichler, T. Pemovska, C. Schweicker, D. Poeloeske, D. Jungherz, , R. Moriggl

This study identifies STAT5 gain-of-function mutations as drivers of T-ALL by promoting pre-TCR signaling and shows therapeutic targeting potential with STAT3/5 or ZAP70 inhibitors.

bioRxiv · Dec 21, 2022 · PreprintCancer Biology

A JAK/STAT-Mediated Inflammatory Signaling Cascade Drives Oncogenesis In AF10-Rearranged AML

B. Chen, A. Deshpande, K. O. Barbosa, M. Kleppe, X. Lei, N. Yeddula, A. Rosa Campos, R. Wechsler-Reya, A. Bagchi, S. Meshinchi, C. J. Eaves, I. Jeremias, T. Haferlach, D. Frank, Z. Ronai, , A. Deshpande

This study identifies JAK1 as a therapeutic target in AF10-rearranged AML by showing its role in JAK/STAT-mediated inflammatory signaling and oncogenesis.

bioRxiv · Aug 31, 2020Cancer Biology